Bariatric Endoscopy and NAFLD

Obesity Clinical Trial

Official title:

Influence of Bariatric Endoscopy on Clinical Course of NAFLD

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04895943
• Other study ID #: 04_RVO-FNOs_2021
• Status: Active, not recruiting
• Start date: April 29, 2021
• Est. completion date: December 31, 2024

Study information

• Verified date: January 2024
• Source: University Hospital Ostrava
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Find out how bariatric endoscopy will influence the clinical course of non-alcoholic fatty liver disease.

Description:

The study will test and investigate the impact of bariatric endoscopy (various types of intragastric balloons, endoscopic sleeve gastroplasty, aspiration therapy) on components of the metabolic syndrome in obese patients, especially on influencing non-alcoholic steatosis and steatohepatitis and signs of liver fibrotization and weight reduction. The method consists of performing a mini-invasive endoscopic procedure and, as a result, reduced food intake.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 60
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age between 21-70 years
• BMI >27 Kg/m2
• Must be able to comply with all study requirements for the duration of the study as outlined in the protocol. This includes complying with the visit schedule as well as study-specific procedures such as clinical assessment, endoscopy, radiography, as well as laboratory investigations
• Must be able to understand and be willing to provide written informed consent
• Patient living within radio range 300 km from the study center
• Failure of the cognitive-behavioral approach to weight reduction Exclusion Criteria: Subjects meeting any of the following exclusionary criteria cannot be enrolled in the

study:

• BMI <27
• History of gastric surgery.
• Previous technical difficulties in gastric and duodenal endoscopy or inability to perform endoscopy
• History of GIT diseases such as achalasia, esophageal motility disorders, severe esophagitis or gastritis, the recent history of ulcers, history of steatosis or obstruction in the GIT
• Proven celiac disease
• Previous irreversible endoscopic procedures and surgical treatment of obesity
• Chronic and acute pancreatitis
• Active or chronic infectious hepatitis
• Known liver disease or suspected PBC, PSC, autoimmune hepatitis, alpha1-antitrypsin deficiency, Wilson's disease, hereditary hemochromatosis, known cirrhosis or history of hepatic decompensation, AST or ALT> 5-8x ULN
• Type 1 or type 2 diabetes with insulin
• History of malignant disease
• Specific genetic or hormonal disorders associated with obesity (Prader-Willi syndrome, MC4R mutations, etc.)
• Serious disorders of blood clotting and hematopoiesis
• Severe forms of psychiatric illness (endogenous depression, schizophrenia, suicidal tendencies, psychosis)
• Uncontrolled hypertension (systolic BP> 150 mm Hg or diastolic BP> 100 mm Hg) or severe heart disease (severe cardiac dysfunction, etc.)
• Serious autoimmune diseases or long-term use treated with glucocorticoids or immunosuppressive therapy
• Disorders of thyroid function unresponsive to processing.
• Renal impairment with GFR <60 ml / min / 1.73 m2, or albumin excretion> 1000 mg / day
• Substance use including excessive alcohol use (> 21 units / week for men and> 14 units / week for women, - 1 unit (250ml 12 ° or 330ml 10 ° beer; 100ml wine; 25ml = small spirits of spirits))
• Pregnancy

Related Conditions & MeSH terms

• Fatty Liver
• Fibrosis
• Liver Cirrhosis
• Liver Fibrosis
• Liver Steatosis
• NAFLD
• Non-alcoholic Fatty Liver Disease
• Obesity

Intervention

Procedure:
• bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
• bariatric endoscopy, mainly intragastric balloons, plication of the stomach too
bariatric endoscopy, mainly intragastric balloons, plication of the stomach too

Locations

Country	Name	City	State
Czechia	University Hospital Ostrava	Ostrava	Moravian-Silesian Region

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital Ostrava

Country where clinical trial is conducted

Czechia, 

References & Publications (3)

Fakhry TK, Mhaskar R, Schwitalla T, Muradova E, Gonzalvo JP, Murr MM. Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysis. Surg Obes Relat Dis. 2019 Mar;15(3):502-511. doi: 10.1016/j.soard.2018.12.002. Epub 2018 Dec 6. — View Citation

Leoni S, Tovoli F, Napoli L, Serio I, Ferri S, Bolondi L. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis. World J Gastroenterol. 2018 Aug 14;24(30):3361-3373. doi: 10.3748/wjg.v24.i30.3361. — View Citation

Machytka E, Klvana P, Kornbluth A, Peikin S, Mathus-Vliegen LE, Gostout C, Lopez-Nava G, Shikora S, Brooks J. Adjustable intragastric balloons: a 12-month pilot trial in endoscopic weight loss management. Obes Surg. 2011 Oct;21(10):1499-507. doi: 10.1007/s11695-011-0424-z. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with NAFLD with degree of fibrosis of the liver among patients undergoing bariatric endoscopy and to determine the influence of bariatric endoscopy on clinical course of NAFLD and liver fibrosis	Number of patients with NAFLD with degree of fibrosis of the liver among patients undergoing bariatric endoscopy and to determine the influence of bariatric endoscopy on clinical course of NAFLD and liver fibrosis	24 months
Secondary	Influence of bariatric endoscopy on change of weight	Influence of bariatric endoscopy on change of weight	24 months
Secondary	Influence of bariatric endoscopy on change of anthropometric parameters	Influence of bariatric endoscopy on change of anthropometric parameters	24 months
Secondary	Anthropometric changes - weight (kg), BMI (kg/m2)	Anthropometric changes - weight (kg), BMI (kg/m2)	24 months
Secondary	Anthropometric changes - waist and hip circumference (cm)	Anthropometric changes - waist and hip circumference (cm)	24 months
Secondary	Nutritional changes (eating habits) - questionnaire survey.	Nutritional changes (eating habits) - questionnaire survey.	24 months
Secondary	Components of the metabolic syndrome - blood pressure (mm/Hg)	Components of the metabolic syndrome - blood pressure (mm/Hg)	24 months
Secondary	Components of the metabolic syndrome - waist circumference (cm)	Components of the metabolic syndrome - waist circumference (cm)	24 months
Secondary	Components of the metabolic syndrome - triacylglycerol levels (mmol/l), HDL cholesterol levels (mmol/l), glycemia (mmol/l)	Components of the metabolic syndrome - triacylglycerol levels (mmol/l), HDL cholesterol levels (mmol/l), glycemia (mmol/l)	24 months